<DOC>
	<DOCNO>NCT02607072</DOCNO>
	<brief_summary>Background : Evidence high quality suggest acetylsalicylic acid ( ASA ) /aspirin effectively reduces colorectal adenoma incidence recurrence rate , several randomize control trial ( RCTs ) strongly indicate potential prevent colorectal cancer ( CRC ) initiation progression decrease cancer-related mortality . However role aspirin supply adjuvant agent postsurgical CRC patient remain obscure , RCT warrant clarification . Aim : The APREMEC trial aim investigate potential preventative role enteric-coated aspirin ( 100 mg 200 mg daily ) postsurgical recurrence metastasis among Asian CRC patient . Design : The investigator hypothesize large-scale multicenter randomize double-blind placebo-controlled trial support aspirin reduce recurrence metastasis improve survival postsurgical non-metastasized CRC patient . The primary endpoint trial disease-free survival , secondary endpoint 3-year 5-year overall survival , interactive effect lifestyle include smoke alcohol ingestion , adverse event rate . Eligible postoperative patient non-metastasized CRC randomize trial 100 mg aspirin , 200 mg aspirin placebo recurrence/metastasis , severe adverse event , death , end study , standard adjuvant therapy . Individuals peptic ulcer , bleed tendency , previous ongoing treatment aspirin anticoagulant exclude trial . Stratification factor gender , study center , cancer site , tumor stage . After randomization , patient follow evaluation 3-month interval take study drug . Discussion : This study aim investigation aspirin 's role adjuvant agent prevention postsurgical CRC recurrence metastasis . If result turn positive , Asian global CRC patient greatly benefit , due fact aspirin inexpensive , easily-accessible , simply-administered , well know manage adverse event .</brief_summary>
	<brief_title>Aspirin Prevention Postsurgical Recurrence Metastasis Asian Colorectal Cancer Patients : Multi-center Randomized Trial</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>This doubleblind , placebocontrolled , randomize trial investigate aspirin application tumornodalmetastasis ( TNM ) stag IIII CRC without metastasis require surgical resection . Patients ≥ 18 year primary tumor ( metastatic lymph node ) completely remove R0 resection margin , complete standard adjuvant therapy within 3 month without bleed potential ( e.g. , platelet count ≥ 100 000/mm3 ) contradiction aspirin eligible trial . Patients allergic aspirin , receive previous ( within 3 month surgery ) ongoing treatment aspirin , antiplatelet anticoagulation agent , Cox inhibitor , glucocorticoid , drug severely interfere aspirin , peptic ulcer , inflammatory bowel disease ( e.g. , ulcerative colitis Crohn 's disease ) , asthma , ischemic heart disease ( IHD ) , class III/IV heart failure ( defined New York Heart Association ) , stroke , thrombotic event , peripheral vascular disease , uncontrolled hypertension , gout severe liver renal dysfunction , undergone coronary artery bypass graft within 3 month exclude trial . Other exclusion criterion : colorectal nonmalignant disease ( e.g. , familial adenomatous polyposis , adenoma ) ; recurrent CRC ; previous colorectal resection ; malignancy CRC ( exclude nonmelanoma skin cancer ) within 5 year intake initiation ; pregnancy nursing ; immunosuppressive therapy within 6 month ; enrollment CRC clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>APREMEC , aspirin , colorectal cancer , adjuvant therapy , recurrence , metastasis , survival</keyword>
</DOC>